Tracers / [212Pb]Pb-212-F3-C25
[212Pb]Pb-212-F3-C25
Also written as Pb-212-F3-C25
- Radionuclide
- Pb-212 t½ 638.4 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 0
What it is
- Compound class
- TCMC-conjugated monoclonal antibody (isotype-matched control mAb)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [212Pb]Pb-212-F3-C25, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 28104527: 'TCMC-mAb F3-C25'. Stage 25: this agent has NO own synthesis/characterisation data in the current corpus -- the model's own extraction reasoning confirms F3-C25 appears in every linked article solely as a non-targeting isotype-control antibody compared against the real therapeutic agents (212Pb-376.96, 212Pb-225.28) -- never characterised itself. All previously-linked runs were unlinked (see parsed-therapy.xlsx).